Tri Harbor Holdings Corp., trading as Actylis, engages in the research and development (R&D), marketing, sale, and distribution of human health products, pharmaceutical ingredients, and specialty chemicals. The company offers active pharmaceutical ingredients to various generic drug companies; crop protection products that include herbicides, fungicides, insecticides, and post-harvest products; cell culture ingredients; GMP excipients to the life sciences industry that are used in vaccines, injectables, dermal, transdermal, topical, and solid dosage finished drugs; and amino acids, supplements, botanical extracts, minerals, vitamins, and others. The company also provides pharmaceutical intermediates; supplies coatings, composites, and plastics; adhesives and sealants; intermediates for synthesis; metal working and metal surface treatment products; printing inks and colors; oil field services products; fuel additives and lubricants; cosmetics and personal care products; electronics; water treatment; and food, flavor, and fragrance products. In addition, it performs routine and non-routine analytical testing for various industries in support of manufacturing processes, QA/QC functions, R&D projects, and environmental applications; provides contract manufacturing services; and offers GMP, biopharma, and non-GMP specialty chemical custom ingredient research and development services. The company serves clients in agriculture, cosmetics, general industry, life science, and nutrition markets in the United States and internationally. The company was formerly known as Aceto Corporation and changed its name to Tri Harbor Holdings Corp. in October 2019. The company was incorporated in 1947 and is based in Port Washington, New York.